Towa Pharmaceutical completed the acquisition of the generics unit of Esteve for $354m.

Towa Pharmaceutical, a company specializing in generic drugs and based in Kadoma, Osaka, completed the acquisition of the generics unit of Esteve, a Spanish pharmaceutical company, for $354m. "I am happy that we can now build a foundation for full-scale overseas expansion by obtaining the sales networks that Pensa owns in Europe and the US, its know-how and knowledge on EMA/FDA regulations and commercial practices in each country, and its production facility in Europe. Our goal is to build a solid global structure by respecting and integrating one another's human resources, culture, and technologies. We will work unitedly as a group to provide Towa's value-added products to patients all over the world," Itsuro Yoshida, Towa President.